Check for updates

OPEN ACCESS

EDITED BY Wei Wu, Indiana University Bloomington, United States

REVIEWED BY Sonia Cortassa, National Institutes of Health (NIH), United States Xia Yu, First Affiliated Hospital of Jinan University, China

*CORRESPONDENCE Yangyang Zhang, i zhangyangyang_wy@vip.sina.com Changfa Guo, i guo.changfa@zs-hospital.sh.cn

[†]These authors have contributed equally to this work

SPECIALTY SECTION This article was submitted to Mitochondrial Research, a section of the journal Frontiers in Physiology

RECEIVED 14 December 2022 ACCEPTED 20 March 2023 PUBLISHED 04 April 2023

CITATION

Liu W, Hu B, Wang Y, Zhang X, Zhu M, Shi Y, Guo C and Zhang Y (2023), Multiple targets related to mitochondrial function unveiled by metabolomics and proteomics profiles of hearts from atrial fibrillation patients. *Front. Physiol.* 14:1123391. doi: 10.3389/fphys.2023.1123391

COPYRIGHT

© 2023 Liu, Hu, Wang, Zhang, Zhu, Shi, Guo and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Multiple targets related to mitochondrial function unveiled by metabolomics and proteomics profiles of hearts from atrial fibrillation patients

Weizhuo Liu^{1†}, Bo Hu^{2†}, Yuliang Wang^{3†}, Xiaobin Zhang⁴, Miao Zhu⁵, Yu Shi⁶, Changfa Guo⁵* and Yangyang Zhang⁴*

¹Department of Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, ³Department of Immunology, Nanjing Medical University, Nanjing, China, ⁴Department of Cardiovascular Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁵Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, ⁶Department of Cardiovascular Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, ⁶Department of Cardiovascular Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China

Background: The prominent mitochondrial metabolic changes of the atrium reportedly have significant impact on electrical signals and structural remodeling which play important roles in the occurrence and development of atrial fibrillation (AF). However, the mechanism is not completely known.

Objective: This study was aimed to explore the mitochondrial metabolism reprogrammed in AF patients by integrating metabolomics as well as proteomics of human atrium tissues.

Methods and Results: Left atrial tissue samples were harvested from 10 nonvalvular AF patients and 10 matched samples from healthy donors for transplantation. In metabolomics analysis, 113 metabolites were upregulated and 10 metabolites were downregulated in AF, where multiple pathways related to mitochondrial energy metabolism were enriched. Correlation analysis between the differentially expressed proteins and metabolites identified several hub proteins related to mitochondrial function including Glycerol-3-phosphate dehydrogenase 2 (GPD2), Synemin (SYNM), Plectin (PLEC), with MCC score of 27, 17, 16, respectively, which have the most interactions with the dysregulated metabolites and ranked at the top in network string interactions scored by MCC method. All 330 differentially expressed proteins including 225 upregulated and 105 downregulated molecules were revealed and analyzed, which identified the downregulation of GPD2 (p = 0.02 and FC = 0.77), PLEC (p < 0.001 and FC = 0.71) and SYNM (p =0.04 and FC = 0.76) in AF patients. Gene Set Variation Analysis (GSEA) showed

Abbreviations: AF, Atrial Fibrillation; BSA, Body surface area; CAD, Coronary artery disease; DEGs, Differential expression genes; DEPs, Differentially expressed proteins; DM, Diabetes mellitus; ECG, Electrocardiograph; GPD2, Glycerol-3-phosphate dehydrogenase 2; GSVA, Gene Set Variation Analysis; HIS, Hospital Information System; HTN, Hypertension; KEGG, Encyclopedia of Genes and Genomes; LAA, Left atrial appendages; LAD, Left atrial diameter; LVEF, Left ventricular ejection fraction; MS, Mitral stenosis; MV, Mitral valve; NAFLD, Non-alcoholic fatty liver disease; NYHA, New York Heart Association; PLEC, Plectin; SR, Sinus Rhythm; SYNM, Synemin.

mitochondrial metabolism-associated pathways including oxidative phosphorylation (NES: –1.73) and ATP biosynthetic process (NES: –2.29), were dramatically diversified in human AF. In GSVA, the expression levels of GPD2, PLEC, and SYNM were demonstrated to be associated with multiple metabolic pathways related to mitochondrial function (e.g., lipid metabolism and AMP activated protein kinase signaling) and cardiac structural and electrical remodeling (e.g., contractile fiber, ion homeostasis), which were proven vital in the development and maintenance of AF.

Conclusion: In all, this study provides new insights into understanding the mechanisms of AF progression, especially the reprogramming mitochondrial metabolism, and identifies several genes related to mitochondrial function as novel targets for AF, which may be involved in the occurrence and development of AF.

KEYWORDS

atrial fibrillation, proteomics, metabolomics, mitochondrial function, multiple targets

Introduction

Atrial fibrillation (AF) is the most common arrhythmia managed in clinical practice with 22%–26% estimated lifetime risk, and is associated with substantial morbidity and increased mortality due to the combination of altered hemodynamics, atrioventricular dyssynchrony, progressive atrial and ventricular mechanical dysfunction, and thromboembolic complications (Hindricks et al., 2020; Brundel et al., 2022). The rising burden of AF, together with the significant increase in coexisting chronic cardiovascular conditions, is evidenced by a global uptrend in AF hospitalization (Kornej et al., 2020).

Atrial remodeling is considered as the most important mechanism involved in the development and progression of AF, including structural and electrical remodeling (Chen et al., 2021a). Recent studies show the metabolic changes of the atrium, especially the mitochondrial metabolism, significantly impact the electrical signaling and structural remodeling of the atrium, and play important roles in the occurrence and development of AF (Bai et al., 2019; Mason et al., 2020; Yuan et al., 2020). In addition, various metabolic disorders (i.e., obesity, diabetes mellitus, and hyperthyroidism) have been proved as risk factors of AF (Lavie et al., 2017; Wang et al., 2019; Lin et al., 2021), through the mechanism of mediating myocyte hypertrophy or fibrosis, etc. (Karam et al., 2017; Sagris et al., 2021). Thus, metabolic disorders play an important role in the occurrence and development of AF (Hajhosseiny et al., 2015; Zheng et al., 2021). However, it is unclear what kind of specific alternation of the metabolism profile is associated with the development of AF, indicating further explorations are required.

The omics technology can generate a large amount of multidimensional data that are amenable to be analyzed by new informatics methods, which have recently been applied to explore the molecular changes and identify the mechanism of AF-related remodeling (Jiang et al., 2019; Liu et al., 2020a; Roselli et al., 2020). As important supplements to genomics and transcriptomics, metabolomics and proteomics are more sensitive to external factors and can better reflect the real physiological state of biological systems (McGarrah et al., 2018; Liu et al., 2020b). In addition, the rapidly-developing mass spectrometry (MS)-based omics techniques provide new tools for numerous metabolite or protein level patterns in biological samples (Challen and Cramer, 2022) and offer more valuable data for biomarker screening and

pathological exploration in AF, especially by multi-omics at the myocardial tissue level, for which data are limited.

In this study, integrated multi-omics analysis of metabolomicsproteomics of human atrium tissues were performed and analyzed to explore the metabolism reprogramed in AF patients and describe the key dysregulated metabolites and proteins as well as related metabolic pathways in AF patients relative to patients with sinus rhythm (SR).

Methods

Statement on human specimens

Left atrial appendages (LAAs) were harvested from AF patients undergoing surgical ablation of AF without cardiopulmonary bypass. Subjects (10 patients) diagnosed with non-valvular (without moderate to severe mitral valve stenosis or prosthetic valve) AF suffered from persistent AF for more than 1 year. For comparison, LAAs from 10 matched SR patients were collected. The controls in SR were matched by age and gender. Normal left atrial appendages were collected from healthy donors. The specimens obtained from the homograft bank had been rejected for clinic use and therefore allocated for research. As required in the research ethics, the clinical criteria for the healthy donors rejected for transplantation including failure in pairing between the donor and recipient of blood matching, etc., or the recipient has been already evaluated not suitable for receiving transplantation anymore due to worsening condition with multiple organs failure and unable to tolerate the surgery, or the recipient had died before the donor arrived. The specimens were immediately snapfrozen and stored in liquid nitrogen (Figure 1). Related clinical information was collected from the Hospital Information System (HIS).

This study was approved by the Ethics Committee Board of Shanghai East Hospital (Approval No. 0402017), and performed in line with the Declaration of Helsinki.

Proteomics and metabolomics analysis

Raw proteomics data were processed using MaxQuant_2.1.0.0, Perseus 2.0.7.0 and R package MSstats 4.4.1. Raw metabolomics data were analyzed using xcms 3.18.0. The overall proteomic and





metabolic changes in AF were determined by OPLS-DA on R package mixOmics (Rohart et al., 2017). Additionally, univariate analysis of Wilcoxon Mann-Whitney U test was conducted for differential analysis.

Dysregulated metabolites and proteins were selected and mapped into the Small Molecule Pathway Database (SMPDB) (http://www.smpdb.ca/) and Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://home.jp/kegg/) for pathway



FIGURE 3

Pathway enrichments of differently expressed metabolites in non-valvular AF compared to SR group. (A–B) Pathways enrichened of the upregulated metabolites in the positively- and negatively-ionized modes, respectively. (C–D) Pathways enrichened of the downregulated metabolites in the positively- and negatively-ionized modes, respectively.



enrichment analysis using R package MetaboAnalystR 3.2.0. Multi-omics analysis of pathways sharing both significant proteins and metabolites using MetaboAnalyst using up- or downregulated proteins and metabolites. Gene Set Enrichment Analysis (GSEA) was also used to analyze the correlations of different gene sets with GSEA 4.1.0. Gene Set Variation Analysis (GSVA) was used to study correlations using R package GSVA 1. 44.5.



The correlative metabolites between metabolomics and proteomics were screened out by spearman correlation analysis using R package psych 2.2.9. All the nodes were loaded to

CytoScape for network construction in the light of the correlation data.

Statistical analysis

Data are presented as mean \pm standard error of the mean (SEM) for at least 3 or 5 independent assays unless otherwise noted. All data passed the normality and equal variance before analysis. Student's t-test was used for 2-sample comparison. One-way analysis variance (ANOVA) with Tukey *post hoc* tests was used for comparisons among multiple groups. Two-way ANOVA was used for comparisons among multiple groups when there were 2 experimental factors. p < 0.05 was considered as statistically significant. Bioinformatic analysis was performed using R 4.2.1 and Rstudio 2022.07.1 Build 554. Cytoscale 3.9.1 was used to construct networks for correlation analysis.

Results

In this study, multiple targets and pathways related to mitochondrial function were unveiled and enriched by metabolomics and proteomics profiles of hearts from atrial fibrillation patients including oxidative phosphorylation and ATP biosynthetic process, *etc.*, which have vital functions in maintaining the homeostasis of the myocardium (Covian and Balaban, 2012; Mason et al., 2020), providing a comprehensive analysis of proteomics and metabolomics landscape of human AF.

LAA samples were harvested from 10 persistent non-valvular AF patients during surgical ablation of atrial fibrillation and 10 SR samples matched by age and gender from healthy donors. Metabolomic analyses were then carried out using the 10 AF samples and the 10 SR samples. Differential metabolites were identified with the criteria of |logFC| > 0.263 and p < 0.05. There were 113 significantly upregulated metabolites and 10 significantly





downregulated metabolites in AF patients compared to the SR group. Especially, the alterations of Raffinose, Adenine and D-Mannitol with FCs of 0.36, 0.44, and 0.22, respectively, are associated with mitochondrial energy metabolism (Figure 2 and Supplementary Table S1).

Moreover, the altered metabolites in AF were enriched in multiple pathways related to mitochondria and glycolipid metabolism. Notably, among the downregulated metabolites in both positively- and negatively-ionized modes in AF patients, pathways including mitochondrial beta-oxidation, fatty acid metabolism and galactose metabolism were enriched (Figure 3). Moreover, pathways associated with various important amino acid metabolisms were enriched, with the upregulated metabolites, such as beta-alanine metabolism, histidine metabolism, and glycine and serine metabolism (enrichment scores 5.58, 4.425 and 1.923 respectively).

Analysis of pathways sharing both significant proteins and metabolites using MetaboAnalyst was then performed. As a result, multiple glycolipid metabolic pathways, such as glycerophospholipid metabolism and glycerolipid metabolism were mostly enriched using the downregulated proteins and metabolites (Figure 4), and various important amino acid metabolic pathways were significantly enriched using the upregulated metabolomics and proteomics profiles (Supplementary Figure S1), consistent with the results of metabolites analysis.

Proteomics samples and metabolomic samples were then sent to correlation analysis using interaction networks of proteins with p < 0.05 and metabolites with VIP >1 and p < 0.05. Correlations with the top 100 r values and p < 0.05 were next constructed, which demonstrated obvious clustering patterns of proteins and metabolites that represented the metabolism changes in AF. Network diagram was drawn on Cytoscape by sorting the absolute values of correlation coefficient (Figure 5B, Supplementary Figure S2 and Supplementary Tables S2, S3). As a result, several hub proteins with metabolites were identified, among which glycerol-3-phosphate dehydrogenase 2 (GPD2) was found at the top of the network string interactions ranked by maximal clique centrality (MCC) method in positively-ionized mode (MCC score = 27; Figures 5A, C), which is located at the inner membrane of mitochondria and closely related to mitochondria energy metabolism (Mráček et al., 2013; Ishihama et al., 2021; Liu et al., 2021). Together with GPD2, SYNM ranked at the top three (MCC score = 17,16, respectively) as well, which have also been reported to be associated with mitochondrial function (Winter et al., 2015; Kuznetsov et al., 2020; Paulin et al., 2020; Baek et al., 2021), indicating its potential participation of mitochondria metabolism in AF.

Proteomics samples were tested by univariate analysis using the criteria for differentially expressed proteins (DEPs): p < 0.05 and logFC >0.263 for upregulation, and p < 0.05 and logFC < -0.263 for downregulation. All 330 DEPs including 225 upregulated DEPs and 105 downregulated DEPs were analyzed, which identified the downregulation of GPD2 (p = 0.02 and FC = 0.77), PLEC (p < 0.001 and FC = 0.71) and SYNM (p = 0.04 and FC = 0.76) in AF patients in AF patients (Figure 6 and Supplementary Table S4).

Pathway enrichment analysis was then performed. For biological processes (BP) by GO analysis, DEPs were enriched in heart development, respiratory electron transport chain and actomyosin structure organization (Figures 7A–C). For cellular components (CC), DEPs were enriched in mitochondrial protein containing complex, organelle inner membrane, and mitochondrial proton transporting ATP synthase complex coupling factor. For molecular functions (MF), DEPs were enriched in proton transmembrane transporter activity, active transmembrane transporter activity and inorganic molecular entity transmembrane transporter activity.

Moreover, oxidative phosphorylation and cardiac muscle contraction were enriched by KEGG (Figure 7D). Ion channel



transport, and organelle biogenesis and maintenance were enriched by REACTOME (Figure 7E). Oxidative phosphorylation was enriched with the largest score (NES = -2.47) by WIKI (Figure 7F). GSEA for function enrichment showed several pathways related to mitochondrial energy metabolisms were significantly downregulated in AF samples, including oxidative phosphorylation (p < 0.01), ATP biosynthetic process (p < 0.01) and NADH dehydrogenase complex (p < 0.01) (Figure 8), which were also reportedly associated with the function of GPD2 (Mráček et al., 2013; Ishihama et al., 2021; Liu et al., 2021).

Gene Set Variation Analysis (GSVA) was then carried out to analyze the correlation of enriched gene sets and the expression of GPD2, PLEC, and SYMN (Figure 9). The GPD2 expression level was associated with multiple pathways related to cardiac structural remodeling [e.g., contractile fiber (r = 0.33), cardiac muscle contraction (r = 0.2)], and various pathways relevant to myocardial electrical remodeling, including calcium signaling (r = 0.27) and ion homeostasis (r = 0.7), and metabolic pathways such as lipid metabolism (r = 0.28) and AMP activated protein kinase signaling (r = 0.46). The expression levels of SYNM showed association with pathways related to cardiac remodeling and energy metabolism [e.g., cardiac muscle contraction (r = 0.38), ion homeostasis (r = 0.71), lipid metabolism (r = 0.28)], and PLEC demonstrated association with pathways related to mitochondria function [e.g., oxidative phosphorylation (r = 0.43), ATP biosynthetic process (r = 0.48)].

Discussion

Metabolism reprogramming in AF

AF is a source of significant morbidity and mortality associated with heart failure, stroke, and other complications (Hindricks et al.,



2020; Brundel et al., 2022). Atrial remodeling including structural and electrical remodeling is among the most important mechanisms involved in the development and progression of AF (Chen et al., 2021a).

AF-induced irregular heartbeat alters atrial hemodynamics, oxygen delivery, and energy supply, which all influence the metabolic state (Kolwicz et al., 2013; Chistiakov et al., 2018). Recent studies demonstrate substantial changes in energy metabolism and metabolism-related enzymes in AF patients compared to patients in sinus rhythm (SR) (Bai et al., 2019; Mason et al., 2020; Yuan et al., 2020). Strong evidence shows that these maladaptive metabolic remodeling activities may represent a driving force for atrial electrical or structural remodeling (McCauley et al., 2020; Chen et al., 2021b; Fang et al., 2022). In a cross-sectional observational study, AF patients had more metabolic complications than the control population matched for age and sex, which are supposed to induce the AF substrate or as a result of AF (Boos, 2020). Nevertheless, the detailed mechanisms remain unclear.

Advantages of multiomics analysis using proteomics and metabolomics

Metabolomics, an emerging type of omics, reflects the downstream products of gene expression and enables a more direct and accurate reflection of the pathophysiological state of an organism. Metabolomics is widely used in new drug development, disease diagnosis, and personalized therapy (Johnson et al., 2016). Proteomics is widely applied into research at large-scale protein levels, and enables researchers to investigate the protein alterations that lead to the pathological progression of diseases (Lindsey et al., 2015). The combination of proteomics and metabolomics enables the analysis of proteins and metabolites involved in the same metabolic pathway, and better reveals the biological processes that an organism produces after a disease or external stimulus, so as to comprehensively and insightfully understand disease processes, cellular physiopathological processes, and regulatory networks to reveal the basic rules of life activities.

Metabolomics and proteomics of AF heart tissue

Recent studies show mitochondrial metabolism, the most predominant functional site of energy metabolism in cardiomyocytes, plays an important role in the development of AF (Brown et al., 2021; Yuan et al., 2022). It also regulates the oxidative phosphorylation of various metabolites and influences the contraction and ion homeostasis of myocardial tissues (Avula et al., 2021). Nevertheless, further exploration is still needed.

In this study, multiple metabolites are significantly dysregulated in AF, such as the alterations of Raffinose, Adenine and D-Mannitol with FCs of 0.36, 0.44, and 0.22,

respectively, and are associated with mitochondrial energy metabolism. Moreover, the compensatory relations between amino acid metabolism and glucose-fatty metabolism have been observed in various diseases, which is very important for the energy metabolism homeostasis (Zhou and Tian, 2018; Careau et al., 2021). Recent studies have revealed the disorder of glycolipid metabolism in AF cardiac tissue, such as the Warburg effect, *etc.* (Hu et al., 2019; Liu et al., 2019). In this study, among the downregulated metabolites in AF, pathways related to mitochondrial beta-oxidation, fatty acid metabolism and galactose metabolism were enriched. On the contrary, using the upregulated metabolites, pathways associated with various important amino acid metabolisms were enriched, which may serve as compensatory mechanism for the energy metabolism.

In the proteomics analysis, mitochondria-associated pathways were also significantly enriched using multiple methods, such as the oxidative phosphorylation, ATP biosynthetic process and NADH dehydrogenase complex, indicating the mitochondrial dysfunction may play an important role in the development and maintenance of AF.

Multiple targets related to mitochondrial function uncovered by multi-omics

In the correlation analysis between the differentially expressed proteins and metabolites, several hub proteins related to mitochondrial function were identified, including GPD2, PLEC, and SYNM, which has the most interactions with the dysregulated metabolites and ranked at the top in network string interactions scored by MCC method.

In this study, GPD2 demonstrated with the most interactions with the dysregulated metabolites in both positively- and negatively-ionized modes, which is known as an integral component of the respiratory chain located at inner mitochondrial membrane and connecting mitochondrial and cytosolic processes via the glycerophosphate (GP)-shuttle, playing an important role in cell energy metabolism (Ishihama et al., 2021; Liu et al., 2021). In addition, it participates in multiple cardiac diseases via regulating mitochondrial function (Mráček et al., 2013). PLEC is a versatile cytolinker protein that has been found to be intimately associated with mitochondria and may participate in several cardiac diseases (Winter et al., 2015; Kuznetsov et al., 2020; Baek et al., 2021). SYNM is a new candidate gene and shows numerous sequence polymorphisms, which is considered as an intermediate filament-associated protein and has interconnects with cardiac mitochondria (Paulin et al., 2020). However, their roles in studies on AF remain unclear.

In GSVA, the expression levels of GPD2, PLEC, and SYNM demonstrated association with multiple metabolic pathways related to mitochondrial function (e.g., lipid metabolism and AMP activated protein kinase signaling) and cardiac structural and electrical remodeling (e.g., contractile fiber, ion homeostasis), which were proven vital for the development

and maintenance of AF (Hindricks et al., 2020; Brundel et al., 2022). Moreover, GSVA demonstrated the metabolism reprogramming was closely related to atrial electrical and structural remodeling, indicating its potential role in AF.

In addition, the limitations of this study include that analysis performed with different tools or metrics has not been compared and discussed in this study and function validation based on experimental approach should be carried out in the further study.

Conclusion

This study provides new insights into the mechanisms of AF progression, especially the reprogramming mitochondrial metabolism, and identifies multiple genes related to mitochondrial function as novel targets for non-valvular AF, which may participate in and maintain AF.

Data availability statement

The data presented in the study are deposited in the ProteomeXchange Consortium (http://proteomecentral. proteomexchange.org) *via* the iProX partner repository, accession number PXD041147.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee Board of Shanghai East Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

WL, BH, and YW analyzed data and wrote the paper. YZ and CG designed the research. XZ, MZ, and YS contributed to data collection and data correction. YZ and CG are responsible for the overall content as guarantors. All authors contributed to processed and edited the manuscript. All authors provided critical revisions of the manuscript and approved the final manuscript.

Funding

This study was supported by funds from the National Natural Science Foundation of China (82070337), Shanghai Municipal Natural Science Foundation (20ZR1446100), Interdisciplinary Program of Shanghai Jiao Tong University (No. YG2022QN101) and Nurture Projects for Basic Research of Shanghai Chest Hospital (No. 2022YNJCQ04).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

Avula, U. M. R., Dridi, H., Chen, B. X., Yuan, Q., Katchman, A. N., Reiken, S. R., et al. (2021). Attenuating persistent sodium current-induced atrial myopathy and fibrillation by preventing mitochondrial oxidative stress. *JCI Insight* 6 (23), e147371. doi:10.1172/jci.insight.147371

Baek, A., Son, S., Baek, Y. M., and Kim, D. E. (2021). KRT8 (keratin 8) attenuates necrotic cell death by facilitating mitochondrial fission-mediated mitophagy through interaction with PLEC (plectin). *Autophagy* 17 (12), 3939–3956. doi:10.1080/15548627. 2021.1897962

Bai, F., Liu, Y., Tu, T., Xiao, Y., and Ma, Y. (2019). Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR- α /VLCAD pathway. Lipids Health Dis. 18 (1), 109. doi:10.1186/s12944-019-1059-7

Boos, C. J. (2020). Infection and atrial fibrillation: Inflammation begets AF. *Eur. Heart J.* 41 (10), 1120–1122. doi:10.1093/eurheartj/ehz953

Brown, S. M., Larsen, N. K., Thankam, F. G., and Agrawal, D. K. (2021). Fetal cardiomyocyte phenotype, ketone body metabolism, and mitochondrial dysfunction in the pathology of atrial fibrillation. *Mol. Cell Biochem.* 476 (2), 1165–1178. doi:10.1007/s11010-020-03980-8

Brundel, B. J. J. M., Ai, X., Hills, M. T., Kuipers, M. F., Lip, G. Y. H., and de Groot, N. M. S. (2022). Atrial fibrillation. *Nat. Rev. Dis. Prim.* 8 (1), 21. doi:10.1038/s41572-022-00347-9

Careau, V., Halsey, L. G., Pontzer, H., Ainslie, P. N., Andersen, L. F., Anderson, L. J., et al. (2021). Energy compensation and adiposity in humans. *Curr. Biol.* 31 (20), 4659–4666.e2. doi:10.1016/j.cub.2021.08.016

Challen, B., and Cramer, R. (2022). Advances in ionisation techniques for mass spectrometry-based omics research. *Proteomics* 22 (15-16), e2100394. doi:10.1002/pmic.202100394

Chen, Y., Lüttmann, F. F., Schoger, E., Scholer, H. R., Zelarayan, L. C., Kim, K. P., et al. (2021). Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice. *Science* 373 (6562), 1537–1540. doi:10.1126/science. abg5159

Chen, Y. C., Voskoboinik, A., Gerche, A., Marwick, T. H., and McMullen, J. R. (2021). Prevention of pathological atrial remodeling and atrial fibrillation: JACC state-of-theart review. J. Am. Coll. Cardiol. 77 (22), 2846–2864. doi:10.1016/j.jacc.2021.04.012

Chistiakov, D. A., Shkurat, T. P., Melnichenko, A. A., Grechko, A. V., and Orekhov, A. N. (2018). The role of mitochondrial dysfunction in cardiovascular disease: A brief review. *Ann. Med.* 50 (2), 121–127. doi:10.1080/07853890.2017.1417631

Covian, R., and Balaban, R. S. (2012). Cardiac mitochondrial matrix and respiratory complex protein phosphorylation. *Am. J. Physiol. Heart Circ. Physiol.* 303 (8), H940–H966. doi:10.1152/ajpheart.00077.2012

Fang, Y., Wu, Y., Liu, L., and Wang, H. (2022). The four key genes participated in and maintained atrial fibrillation process via reprogramming lipid metabolism in AF patients. *Front. Genet.* 13, 821754. doi:10.3389/fgene.2022.821754

Hajhosseiny, R., Matthews, G. K., and Lip, G. Y. (2015). Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic. *Heart rhythm.* 12 (11), 2332–2343. doi:10.1016/j.hrthm.2015.06.038

Hindricks, G., Potpara, T., and Dagres, N. (2020). ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur. Heart J.* 42 (5), 373–498.

Hu, H. J., Zhang, C., Tang, Z. H., Qu, S. L., and Jiang, Z. S. (2019). Regulating the Warburg effect on metabolic stress and myocardial fibrosis remodeling and atrial intracardiac waveform activity induced by atrial fibrillation. *Biochem. Biophys. Res. Commun.* 516 (3), 653–660. doi:10.1016/j.bbrc.2019.06.055

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2023.1123391/ full#supplementary-material

Ishihama, S., Yoshida, S., Yoshida, T., Mori, Y., Ouchi, N., Eguchi, S., et al. (2021). LPL/AQP7/GPD2 promotes glycerol metabolism under hypoxia and prevents cardiac dysfunction during ischemia. *FASEB J.* 35 (12), e22048. doi:10. 1096/fj.202100882R

Jiang, S., Guo, C., Zhang, W., Che, W., Zhang, J., Zhuang, S., et al. (2019). The integrative regulatory network of circRNA, microRNA, and mRNA in atrial fibrillation. *Front. Genet.* 10, 526. doi:10.3389/fgene.2019.00526

Johnson, C. H., Ivanisevic, J., and Siuzdak, G. (2016). Metabolomics: Beyond biomarkers and towards mechanisms. *Nat. Rev. Mol. Cell Biol.* 17 (7), 451–459. doi:10.1038/nrm.2016.25

Karam, B. S., Chavez-Moreno, A., Koh, W., Akar, J. G., and Akar, F. G. (2017). Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. *Cardiovasc Diabetol.* 16 (1), 120. doi:10.1186/s12933-017-0604-9

Kolwicz, S. C., Jr, Purohit, S., and Tian, R. (2013). Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. *Circ. Res.* 113 (5), 603–616. doi:10.1161/CIRCRESAHA.113.302095

Kornej, J., Börschel, C. S., Benjamin, E. J., and Schnabel, R. B. (2020). Epidemiology of atrial fibrillation in the 21st century: Novel methods and new insights. *Circ. Res.* 127 (1), 4–20. doi:10.1161/CIRCRESAHA.120.316340

Kuznetsov, A. V., Javadov, S., Grimm, M., Margreiter, R., Ausserlechner, M. J., and Hagenbuchner, J. (2020). Crosstalk between mitochondria and cytoskeleton in cardiac cells. *Cells* 9 (1), 222. doi:10.3390/cells9010222

Lavie, C. J., Pandey, A., Lau, D. H., Alpert, M. A., and Sanders, P. (2017). Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: Effects of weight loss and exercise. *J. Am. Coll. Cardiol.* 70 (16), 2022–2035. doi:10.1016/j. jacc.2017.09.002

Lin, Y. S., Tsai, H. Y., Lin, C. Y., Wu, V. C. C., Chen, T. H., Yang, T. Y., et al. (2021). Risk of thromboembolism in non-valvular atrial fibrillation with or without clinical hyperthyroidism. *Glob. Heart* 16 (1), 45. doi:10.5334/gh.871

Lindsey, M. L., Mayr, M., Gomes, A. V., Delles, C., Arrell, D. K., Murphy, A. M., et al. (2015). Transformative impact of proteomics on cardiovascular Health and disease: A scientific statement from the American heart association. *Circulation* 132 (9), 852–872. doi:10.1161/CIR.00000000000226

Liu, B., Li, X., Zhao, C., Wang, Y., Lv, M., Shi, X., et al. (2020). Proteomic analysis of atrial appendages revealed the pathophysiological changes of atrial fibrillation. *Front. Physiol.* 16 (11), 573433. doi:10.3389/fphys.2020.573433

Liu, B., Shi, X., Ding, K., Lv, M., Qian, Y., Zhu, S., et al. (2020). The joint analysis of multi-omics data revealed the methylation-expression regulations in atrial fibrillation. *Front. Bioeng. Biotechnol.* 12 (8), 187. doi:10.3389/fbioe.2020.00187

Liu, S., Fu, S., Wang, G., Cao, Y., Li, L., Li, X., et al. (2021). Glycerol-3-phosphate biosynthesis regenerates cytosolic NAD+ to alleviate mitochondrial disease. *Cell Metab.* 33 (10), 1974–1987. e9. doi:10.1016/j.cmet.2021.06.013

Liu, Y., Bai, F., Liu, N., Ouyang, F., and Liu, Q. (2019). The Warburg effect: A new insight into atrial fibrillation. *Clin. Chim. Acta* 499, 4–12. doi:10.1016/j.cca.2019.08.029

Mason, F. E., Pronto, J. R. D., Alhussini, K., Maack, C., and Voigt, N. (2020). Cellular and mitochondrial mechanisms of atrial fibrillation. *Basic Res. Cardiol.* 115 (6), 72. doi:10.1007/s00395-020-00827-7

McCauley, M. D., Hong, L., Sridhar, A., Menon, A., Perike, S., Zhang, M., et al. (2020). Ion Channel and structural remodeling in obesity-mediated atrial fibrillation. *Circ. Arrhythm. Electrophysiol.* 13 (8), e008296. doi:10.1161/CIRCEP.120.008296

McGarrah, R. W., Crown, S. B., Zhang, G. F., Shah, S. H., and Newgard, C. B. (2018). Cardiovascular metabolomics. *Circ. Res.* 122 (9), 1238–1258. doi:10.1161/ CIRCRESAHA.117.311002 Mráček, T., Drahota, Z., and Houštěk, J. (2013). The function and the role of the mitochondrial glycerol-3-phosphate dehydrogenase in mammalian tissues. *Biochim. Biophys. Acta* 1827 (3), 401–410. doi:10.1016/j.bbabio.2012.11.014

Paulin, D., Hovhannisyan, Y., Kasakyan, S., Agbulut, O., Li, Z., and Xue, Z. (2020). Synemin-related skeletal and cardiac myopathies: An overview of pathogenic variants. *Am. J. Physiol. Cell Physiol.* 318 (4), C709–C718. doi:10.1152/ajpcell.00485.2019

Rohart, F., Gautier, B., Singh, A., and Le Cao, K. A. (2017). mixOmics: An R package for 'omics feature selection and multiple data integration. *PLoS Comput. Biol.* 13 (11), e1005752. doi:10.1371/journal.pcbi.1005752

Roselli, C., Rienstra, M., and Ellinor, P. T. (2020). Genetics of atrial fibrillation in 2020: GWAS, genome sequencing, polygenic risk, and beyond. *Circ. Res.* 127 (1), 21–33. doi:10.1161/CIRCRESAHA.120.316575

Sagris, M., Vardas, E. P., Theofilis, P., Antonopoulos, A. S., Oikonomou, E., and Tousoulis, D. (2021). Atrial fibrillation: Pathogenesis, predisposing factors, and genetics. *Int. J. Mol. Sci.* 23 (1), 6. doi:10.3390/ijms23010006

Wang, A., Green, J. B., Halperin, J. L., and Piccini, J. P., Sr (2019). Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J. Am. Coll. Cardiol. 74 (8), 1107–1115. doi:10.1016/j.jacc.2019.07.020 Winter, L., Kuznetsov, A. V., Grimm, M., Zeold, A., Fischer, I., and Wiche, G. (2015). Plectin isoform P1b and P1d deficiencies differentially affect mitochondrial morphology and function in skeletal muscle. *Hum. Mol. Genet.* 24 (16), 4530–4544. doi:10.1093/ hmg/ddv184

Yuan, M., Gong, M., He, J., Xie, B., Zhang, Z., Meng, L., et al. (2022). IP3R1/GRP75/ VDAC1 complex mediates endoplasmic reticulum stress-mitochondrial oxidative stress in diabetic atrial remodeling. *Redox Biol.* 52, 102289. doi:10.1016/j.redox.2022. 102289

Yuan, M., Gong, M., Zhang, Z., Meng, L., Tse, G., Zhao, Y., et al. (2020). Hyperglycemia induces endoplasmic reticulum stress in atrial cardiomyocytes, and mitofusin-2 downregulation prevents mitochondrial dysfunction and subsequent cell death. Oxid. Med. Cell Longev. 2020, 6569728. doi:10.1155/2020/6569728

Zheng, Y., Xie, Z., Li, J., Chen, C., Cai, W., Dong, Y., et al. (2021). Meta-analysis of metabolic syndrome and its individual components with risk of atrial fibrillation in different populations. *BMC Cardiovasc Disord*. 21 (1), 90. doi:10.1186/s12872-021-01858-1

Zhou, B., and Tian, R. (2018). Mitochondrial dysfunction in pathophysiology of heart failure. J. Clin. Invest. 128 (9), 3716–3726. doi:10.1172/JCI120849